U.S. Markets closed

Genfit SA (GNFT.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
3.2860+0.0580 (+1.80%)
At close: 5:35PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.2280
Open3.2300
BidN/A x N/A
AskN/A x N/A
Day's Range3.2300 - 3.2880
52 Week Range3.0220 - 6.2350
Volume68,213
Avg. Volume93,788
Market Cap150.335M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-2.6050
Earnings DateSep 28, 2021 - Oct 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

    Lille, France; Cambridge, MA; July 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2021: 105,050 shares€646 510.51 During the firs

  • GlobeNewswire

    GENFIT: June 30, 2021 Annual Shareholders Meeting results

    Lille (France); Cambridge (Massachusetts, United States) — June 30, 2021 — GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the results of the voting by shareholders at the Combined Shareholders Meeting which took place on June 30, 2021 behind closed doors at the Company’s headquarters. All of the resolutions were adopted by a wide majority of the votes cast, except f

  • GlobeNewswire

    GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan

    Lille, France; Cambridge, MA; June 24, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the securing of a €11 million non-dilutive loan guaranteed by the French government (known as a State-Guaranteed Loan or Prêt Garanti par l’Etat in French). The loan, granted in the context of the COVID-19 pandemic by a syndicate of French banks, is 90% guaranteed by the French gove